Yumanity Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
40 Guest St Ste 4410, Boston, Massachuse...Phone Number
(617) 409-5300Website
www.yumanity.comRevenue
$5.5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. Yumanity's drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity's pipeline consists of programs focused on Parkinson's disease, Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.Explore more
Popular SearchesYumanity Therapeuticsyumanity therapeutics IncYumanity Therapeutics LLCYumanityYumanity Holdings LLCSIC Code 87,873NAICS Code 54,541Show moreYumanity Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Yumanity Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Yumanity Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Yumanity Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Yumanity Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Yumanity Therapeutics
Check out if Yumanity Therapeutics is spiking on competitors!
Yumanity Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Yumanity Therapeutics launches new products
Check if Yumanity Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Yumanity Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Yumanity Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Yumanity Therapeutics.
Yumanity Therapeutics financials insights
Gather financial insights about Yumanity Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$45M
2020
Debt
$1M
Yumanity Therapeutics Tech Stack
Most Recent Scoops
Left Company
Executive Move
Mergers & Acquisitions (M&A)
Left Company
Executive Move
Layoffs
New Hire
Executive Move
Yumanity Therapeutics News & Media
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments.Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.
Special Meeting of stockholders to approve asset sale and merger to be held on December 13, 2022 Special Meeting of stockholders to approve asset sale and merger to be held on December 13, 2022Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta
BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the filing of a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”).Seattle biotech Kineta will go public in deal with neurosciences company Yumanity Therapeutics
Seattle biotech company Kineta is going public through a merger with Yumanity Therapeutics, a neurosciences company based in Boston. Yumanity will also sell part of its pipeline to Johnson & Johnson’s Janssen division for $26 million in a set of deals announced Monday. The merged company will be called Kineta and will be led by the current Kineta management team, including Kineta CEO Shawn Iodonato and president Craig Philips. Kineta’s existing shareholders are expected to
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Yumanity Therapeutics
Sign Up For FreeTo access detailed company insights
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. Yumanity's drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming th... Read More
